Cell therapies use living cells to treat disease. Some redirect immune cells against cancer; others aim to replace damaged tissue, restore a missing function or control harmful immune activity. For investors, the attraction is clear: a treatment that produces durable benefit after a short course could change patient care and support a valuable business. The difficulty is turning that biological effect into a medicine that can be produced consistently, delivered on time and paid for at a sustainable price.
A promising cell therapy therefore needs assessment at several levels. Does it work in the intended patients? Can the company manufacture it reliably? Can treatment centers deliver it without creating an operational bottleneck? These questions connect, but success on one does not settle the others. Within the broader field of biotech science and drug technologies, cell therapies deserve particular attention because the product, production process and treatment pathway are closely linked.
What distinguishes the main types of cell therapy?
“Cell therapy” describes a broad category, rather than one technology or business model. An engineered immune cell that attacks cancer has different development requirements from a replacement cell intended to produce insulin. Even within cancer treatment, companies may use different cell sources, targeting methods and manufacturing systems. Start by identifying the cell’s intended job. Then establish whether the treatment uses the patient’s own cells, donor cells or cells produced from an established cell bank. Those distinctions shape the evidence needed, the production schedule and the commercial assumptions worth testing.
| Approach | Intended function | Questions for investors |
|---|---|---|
| CAR T cells | T cells receive an engineered receptor that recognizes a target on a cell’s surface. | How selective is the target, how durable is the response, and can production meet demand? |
| T cell receptor therapies | Engineered T cells recognize protein fragments presented by compatible HLA molecules. | How much do antigen expression and HLA eligibility narrow the patient population? |
| Tumor-infiltrating lymphocytes | Immune cells collected from a patient’s tumor are expanded for treatment. | Can patients provide suitable tumor material and complete the treatment pathway? |
| Immune-modulating cells | Cells aim to alter harmful immune activity. | Does measurable biological activity translate into meaningful patient benefit? |
| Replacement cells | Cells aim to restore a lost physiological function. | Will they survive, function safely and remain effective over time? |
Cell therapy also overlaps with gene therapy. Cells may be genetically modified outside the body before administration, making the treatment both a cellular product and a means of delivering a genetic change. Other cell therapies do not require genetic modification. Keep these categories separate when comparing companies: an impressive gene editing result does not establish that the resulting cells can be manufactured economically or delivered successfully. The additional questions around editing accuracy, unwanted changes and delivery belong within an assessment of gene editing technologies.
Autologous versus allogeneic: different production models
Autologous therapies: a patient-linked production cycle
Autologous therapies use the patient’s own cells. The commercial model must connect collection, manufacturing and administration for each patient, with identity maintained throughout. In a typical autologous CAR T process, T cells are collected, engineered, expanded and returned for infusion. Manufacturing availability becomes part of treatment planning. For an investor, the useful unit is a completed patient treatment, rather than a batch started or a collection scheduled. A company may improve production speed while still losing patients elsewhere in the pathway, through disease progression, scheduling delays or a change in clinical eligibility.
This model makes operational disclosures worth reading carefully. Ask when the reported turnaround clock starts and stops. A manufacturing interval measured from receipt of cells at the factory excludes time spent arranging collection and transport. A release-to-delivery measure excludes production altogether. Neither measure is inherently misleading, but they answer different questions. Compare companies using consistent definitions, and separate typical turnaround from the range of outcomes. A short median can coexist with a difficult tail of delayed cases. Patients and treatment centers experience that tail; a presentation slide may not show it.
Allogeneic therapies: inventory first, compatibility still matters
Allogeneic therapies use cells from another person, or cells derived from a donor-origin cell line. Producing doses in advance offers a different operating model: inventory can potentially serve several patients without a new collection for each treatment. That does not eliminate immune compatibility problems. Donor immune cells may attack recipient tissue, while the recipient’s immune system may reject the treatment. Experimental engineering strategies address these risks, including changes to native T cell receptors and HLA expression. The phase 1 study of engineered allogeneic CAR T cells in recurrent high-grade glioma illustrates such strategies; it does not establish that every donor-derived approach will share the same safety or effectiveness.
For valuation, treat lower production costs and faster access as assumptions to prove. Request evidence on doses released per manufacturing run, consistency across donors or cell banks, storage losses and treatment persistence. A large production run can spread fixed costs across many doses. It can also concentrate exposure if that run fails or demand arrives more slowly than forecast. Autologous and allogeneic are therefore operating models with different trade-offs. Neither label, by itself, establishes a better product or a better investment.
Scientific potential: matching the cells to the disease
Cancer treatment depends on more than target recognition
An engineered immune cell must recognize the intended cancer cells and remain functional long enough to produce benefit. Solid tumors add obstacles: uneven target expression, difficulty reaching tumor sites and local conditions that suppress immune activity. A target present on healthy tissue can also create safety concerns. These barriers help explain why a promising laboratory result needs careful clinical confirmation, and why success against one cancer does not validate another. The National Cancer Institute’s CAR T research overview covers these biological barriers and the established blood cancer applications.
The investment question is whether the proposed design addresses a demonstrated cause of treatment failure. Adding another receptor, editing another gene or changing the cell source may have a sound rationale, but each modification needs evidence. Look for data connecting the design change to the intended effect, followed by results in patients who resemble the proposed commercial population. A product’s technical sophistication is not an outcome measure. The same discipline applies when evaluating drug targets and mechanisms of action: biological plausibility starts the argument, patient evidence must carry it further.
Solid tumor approvals do not validate every cellular approach
On February 16, 2024, the FDA granted accelerated approval to Iovance’s lifileucel, marketed as Amtagvi, for previously treated advanced melanoma. The treatment uses tumor-infiltrating lymphocytes collected from a patient’s tumor and expanded outside the body. Its regimen includes lymphodepleting chemotherapy before infusion and IL-2 afterward. This matters commercially because the product cannot be assessed separately from the patient’s ability to undergo the wider regimen. The NCI account of lifileucel’s approval and treatment pathway documents both the scientific advance and the practical constraints.
An approval in melanoma is evidence for that product and indication, not proof that a similar approach will work across solid tumors. For another program, examine its target population, treatment burden and evidence independently. The same caution applies to comparisons between CAR T cells, engineered T cell receptors and tumor-derived lymphocytes. Their methods of recognizing cancer differ. Their patient selection can differ too. An investor should resist turning “cell therapy for solid tumors” into a single market forecast when the underlying products may compete for different patients and require different treatment infrastructure.
Replacement and immune-modulating therapies broaden the opportunity
Cell therapies extend beyond cancer-directed immune cells. On December 18, 2024, the FDA approved Mesoblast’s Ryoncil, a donor-derived bone marrow mesenchymal stromal cell therapy, for steroid-refractory acute graft-versus-host disease in children aged two months and older. The FDA approval announcement for Ryoncil provides a concrete example of an allogeneic cellular medicine outside the CAR T category. It also shows why investors should avoid treating all donor-derived products as if they face identical scientific or commercial questions.
Replacement cells offer another route. A phase 1–2 study of Vertex’s stem cell-derived islet therapy, zimislecel, published in June 2025, reported insulin independence at day 365 in 10 of 12 full-dose recipients with at least one year of follow-up. All participants received immunosuppressive therapy. The original study of stem cell-derived islets for type 1 diabetes supports further investigation, rather than a claim of a broadly applicable cure. For investors, the distinction matters: restoring a biological function is compelling evidence, while durability, safety and the burden of accompanying treatment still determine commercial usefulness.
Reading clinical evidence without losing the denominator
Cell therapy announcements can emphasize results among patients who received treatment. That population matters, but it may exclude patients who entered the pathway and never reached infusion. Check the numbers screened, enrolled, collected and treated, then establish why patients dropped out. A response rate among infused patients answers a different question from the proportion of enrolled patients who received treatment and benefited. The denominator matters, so does the follow-up. An early result from a small group should not be treated as equivalent to a mature dataset with consistent assessment and few missing observations. Apply a structured method for reading clinical trial results.
Durability deserves its own examination. Separate an initial response from a complete response, ongoing disease control and survival. Check whether follow-up is long enough to support the claim being made, how many patients remain under observation and whether later treatments complicate interpretation. For replacement therapies, look for evidence that the cells restore a meaningful function, rather than producing a detectable laboratory signal alone. The appropriate measure depends on the disease and intended benefit. A careful assessment of clinical endpoints helps prevent a convenient biomarker from becoming a substitute for the outcome patients need.
Safety also belongs to the whole regimen. Distinguish effects associated with the cells from those associated with conditioning, supportive medicines or immunosuppression, while retaining the combined burden in the commercial assessment. The relevant comparison is the treatment pathway a physician would choose instead. A manageable adverse event in a specialist trial center may still create staffing, monitoring or access demands during a wider launch. Use consistent severity grades, observation periods and denominators when assessing adverse events and treatment discontinuations.
Regulatory requirements can change without removing the underlying clinical risks. On June 26, 2025, the FDA eliminated REMS programs for six listed BCMA- and CD19-directed autologous CAR T therapies. Boxed warnings for cytokine release syndrome and neurological toxicities remained, and manufacturers’ requirements for observational safety studies with 15 years of follow-up were unchanged. The FDA communication on CAR T REMS elimination is therefore relevant to access assumptions, but it is not evidence that these products have become routine infusions requiring no specialist planning.
Manufacturing: the product has to survive the process
Starting material and traceability
Cell therapy manufacturing begins with biological material, rather than a uniform chemical ingredient. Investors should ask how the company handles variation in the incoming cells and what happens when a collection does not meet expectations. For patient-linked products, distinguish chain of identity from chain of custody. Identity connects the material to the correct patient; custody records its movement and handling. Assess both as operating controls, not administrative details. A useful manufacturing disclosure explains where failures occur, how the company detects them and whether a repeat collection or production attempt is possible. A headline success rate without that context leaves too much hidden.
Viability does not establish potency
A living cell is not necessarily a functioning therapeutic cell. Viability measures whether cells are alive; potency measures biological activity relevant to the intended effect. Identity and purity answer other questions. The EMA guideline on human cell-based medicinal products addresses these distinctions and the role of release testing. For investment analysis, ask whether the potency assay measures an activity linked to the proposed mechanism, how consistent the result is across batches and whether the assay can detect changes introduced during development. A large cell count is not a substitute for evidence that the cells can perform their intended job.
Release testing creates another distinction worth preserving: a batch can be manufactured successfully yet fail to become a released commercial dose. Ask the company to define each reported measure. Does its success rate include batches awaiting testing? Are repeat attempts counted separately? Does “delivered” mean shipped to a center or administered to a patient? These are questions to resolve from company disclosures, rather than reasons to assume poor performance. They are also why investors benefit from a broader assessment of manufacturing capacity, quality control and production costs before assigning value to an announced factory expansion.
Process improvements need a comparability plan
Automation, a new facility or a shorter culture process may improve operating economics. Such changes also require evidence that the resulting product remains comparable. Passing routine release specifications alone does not settle that question. The EMA questions and answers on advanced therapy comparability address process comparisons, new manufacturing sites and circumstances requiring additional nonclinical or clinical data. For investors, a proposed production upgrade should therefore come with a development plan, rather than an immediate assumption of lower costs and unchanged performance.
Timing matters. Ask which version of the process produced the clinical evidence, which will supply the launch and what work connects the two. A company that postpones a major production change may be accepting higher near-term costs to avoid disrupting a trial or submission. Another may need to make the change because its existing process cannot support the intended market. Neither decision can be judged from projected savings alone. Include the time, expenditure and uncertainty associated with the transition when assessing possible regulatory setbacks and additional study requirements.
Commercial constraints: eligible patients must reach treatment
The addressable market should begin with patients who could realistically receive the therapy, rather than everyone with the disease. Work through the relevant restrictions: treatment history, target expression, HLA compatibility where applicable, organ function and fitness for the regimen. Then consider referral and access. Each assumption should have a clear basis, and overlapping exclusions should not be deducted twice. The purpose is to build a patient funnel that can be challenged and updated. A disciplined approach to estimating eligible patients is more useful than multiplying disease prevalence by an ambitious treatment price.
Center capacity is another variable to test. Count centers that are actively treating patients, rather than assuming every announced site contributes equally. Ask about collection availability, staffing, scheduling and the number of completed treatments per center. Adding sites may improve geographic access, but a sales forecast should show how those sites become productive. Conversely, a smaller network with higher throughput may support more treatments than a larger, lightly used network. These are launch assumptions, not facts to infer from a center count. Assess them alongside the broader issues affecting drug launches and physician adoption.
A therapy also competes with the available treatment pathway. A rival medicine may offer less durable benefit but simpler administration, or it may arrive sooner in a patient’s care. Compare evidence quality, treatment setting and patient eligibility before comparing response percentages. Cross-trial figures can reflect different populations and follow-up, rather than a genuine product advantage. A cell therapy’s place in care will depend on the benefit physicians expect relative to its burdens. Build those comparisons into the assessment of standards of care and competing treatments, without assuming that a technically novel product automatically displaces established options.
Price requires similar discipline. Separate the manufacturer’s product revenue from the wider cost of collection, preparation, administration and follow-up. Those costs may fall on different participants in the healthcare system, but they can still affect willingness and ability to deliver treatment. In a forecast, use an explicit net revenue assumption rather than treating an announced list price as cash collected. Then test coverage, payment timing and provider economics where evidence is available. The broader questions belong within drug pricing, reimbursement and market access; they should not disappear simply because the clinical result is compelling.
Testing unit economics with a simple example
Consider a hypothetical autologous manufacturer planning 1,000 production starts in a year. Assume 900 become released doses and 840 patients receive treatment. These figures are illustrative, not industry averages. Suppose the company earns $250,000 in net revenue per completed treatment, incurs $70,000 in variable manufacturing costs per production start and spends another $15 million on fixed manufacturing operations. The purpose of the exercise is to expose the denominators. Revenue follows completed treatments under these assumptions, while much of the production expenditure follows starts. Lost patients and failed batches affect the model differently.
| Measure | Calculation | Illustrative result |
|---|---|---|
| Product revenue | 840 treatments × $250,000 | $210 million |
| Variable manufacturing costs | 1,000 starts × $70,000 | $70 million |
| Fixed manufacturing costs | Assumed annual expenditure | $15 million |
| Manufacturing cost per treated patient | $85 million ÷ 840 patients | Approximately $101,190 |
| Revenue less modeled manufacturing costs | $210 million − $85 million | $125 million |
The $125 million remainder is not operating profit. The example excludes research, selling expenses, administration, financing and other costs; it does not prescribe an accounting gross margin. Its practical use is sensitivity testing. Reduce completed treatments while leaving production starts unchanged, and revenue falls without an equivalent reduction in the modeled manufacturing bill. Increase starts beyond usable capacity, and further expenditure may be needed. For a real company, connect these operating assumptions to its cash burn and cash runway, including expenditure required before a facility contributes revenue.
Questions to resolve before the next investment milestone
Build a short evidence request around the company’s next decision point. Before a trial readout, prioritize patient flow, follow-up and the treatment regimen. Before a manufacturing expansion, prioritize released output and process comparability. Before launch, prioritize referral conversion and completed treatments. The questions should change with the stage of the business. Keeping the same checklist for an early research company and a commercial manufacturer creates false precision, and wastes attention on numbers that do not yet exist.
- Which patients entered the treatment pathway, and how many reached administration?
- Which manufacturing process produced the clinical dataset, and which process will supply the market?
- What do reported capacity and manufacturing success rates actually measure?
- What evidence supports the assumed durability, net revenue and treatment uptake?
Translate unresolved questions into explicit scenarios rather than burying them in one forecast. Test slower patient conversion separately from lower manufacturing yield. Test shorter benefit separately from a lower price. Those changes have different causes and may require different responses from the business. A structured valuation sensitivity analysis can show which missing piece of evidence would change the investment case most. That provides a concrete task for the next filing, clinical update or launch report: obtain the evidence that matters to the model, then revise the assumption it supports.